Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lv, Weiguo
NCT06584032: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer	Recruiting	3	412	RoW	fruquintinib, HMPL-013, sintilimab, IBI308, paclitaxel, doxorubicin	Hutchmed	Advanced Endometrial Cancer	01/29	06/29
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian	Completed	2	150	US, RoW	Paclitaxel, Afuresertib, LAE002	Laekna Limited	Platinum-resistant Ovarian Cancer	07/23	06/24
NCT05551507: IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer	Recruiting	1/2	150	RoW	IN10018 in combination with PLD, IN10018 add on to PLD treatment	InxMed (Shanghai) Co., Ltd.	Platinum-resistant Ovarian Cancer	06/24	12/24